Overall, patients with LGI, GABABR or AMPAR antibodies had clinical features of the encephalitis typically associated with the corresponding antibody (median age 56-62 years, slight male predominance in anti-LGI1 and anti-GABABR, and higher tumor association in anti-GABABR and anti-AMPAR, 40-60%) regardless of the negative findings with the commercial kit (7, 10, 11). This evidence concerns the gene LGI1 and viral encephalitis.